Literature DB >> 23099443

Specific Kv1.3 blockade modulates key cholesterol-metabolism-associated molecules in human macrophages exposed to ox-LDL.

Yong Yang1, Yan-Fu Wang, Xiao-Fang Yang, Zhao-Hui Wang, Yi-Tian Lian, Ying Yang, Xiao-Wei Li, Xiang Gao, Jian Chen, Yan-Wen Shu, Long-Xian Cheng, Yu-Hua Liao, Kun Liu.   

Abstract

Cholesterol-metabolism-associated molecules, including scavenger receptor class A (SR-A), lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), CD36, ACAT1, ABCA1, ABCG1, and scavenger receptor class B type I, can modulate cholesterol metabolism in the transformation from macrophages to foam cells. Voltage-gated potassium channel Kv1.3 has increasingly been demonstrated to play an important role in the modulation of macrophage function. Here, we investigate the role of Kv1.3 in modulating cholesterol-metabolism-associated molecules in human acute monocytic leukemia cell-derived macrophages (THP-1 macrophages) and human monocyte-derived macrophages exposed to oxidized LDL (ox-LDL). Human Kv1.3 and Kv1.5 channels (hKv1.3 and hKv1.5) are expressed in macrophages and form a heteromultimeric channel. The hKv1.3-E314 antibody that we had generated as a specific hKv1.3 blocker inhibited outward delayed rectifier potassium currents, whereas the hKv1.5-E313 antibody that we had generated as a specific hKv1.5 blocker failed. Accordingly, the hKv1.3-E314 antibody reduced percentage of cholesterol ester and enhanced apoA-I-mediated cholesterol efflux in THP-1 macrophages and human monocyte-derived macrophages exposed to ox-LDL. The hKv1.3-E314 antibody downregulated SR-A, LOX-1, and ACAT1 expression and upregulated ABCA1 expression in THP-1 macrophages and human monocyte-derived macrophages. Our results reveal that specific Kv1.3 blockade represents a novel strategy modulating cholesterol metabolism in macrophages, which benefits the treatment of atherosclerotic lesions.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23099443      PMCID: PMC3520537          DOI: 10.1194/jlr.M023846

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  73 in total

1.  ATP-binding cassette transporter A1 (ABCA1) functions as a cholesterol efflux regulatory protein.

Authors:  N Wang; D L Silver; C Thiele; A R Tall
Journal:  J Biol Chem       Date:  2001-04-17       Impact factor: 5.157

2.  Selective targeting of liposomes to macrophages using a ligand with high affinity for the macrophage scavenger receptor class A.

Authors:  Patrick C N Rensen; J C Emile Gras; Eva K Lindfors; Ko Willems van Dijk; J Wouter Jukema; Theo J C van Berkel; Erik A L Biessen
Journal:  Curr Drug Discov Technol       Date:  2006-06

3.  ABCA1 is the cAMP-inducible apolipoprotein receptor that mediates cholesterol secretion from macrophages.

Authors:  J F Oram; R M Lawn; M R Garvin; D P Wade
Journal:  J Biol Chem       Date:  2000-11-03       Impact factor: 5.157

4.  Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases.

Authors:  Christine Beeton; Heike Wulff; Nathan E Standifer; Philippe Azam; Katherine M Mullen; Michael W Pennington; Aaron Kolski-Andreaco; Eric Wei; Alexandra Grino; Debra R Counts; Ping H Wang; Christine J LeeHealey; Brian S Andrews; Ananthakrishnan Sankaranarayanan; Daniel Homerick; Werner W Roeck; Jamshid Tehranzadeh; Kimber L Stanhope; Pavel Zimin; Peter J Havel; Stephen Griffey; Hans-Guenther Knaus; Gerald T Nepom; George A Gutman; Peter A Calabresi; K George Chandy
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-06       Impact factor: 11.205

Review 5.  Potassium channels as therapeutic targets for autoimmune disorders.

Authors:  Heike Wulff; Christine Beeton; K George Chandy
Journal:  Curr Opin Drug Discov Devel       Date:  2003-09

6.  Malondialdehyde alteration of low density lipoproteins leads to cholesteryl ester accumulation in human monocyte-macrophages.

Authors:  A M Fogelman; I Shechter; J Seager; M Hokom; J S Child; P A Edwards
Journal:  Proc Natl Acad Sci U S A       Date:  1980-04       Impact factor: 11.205

7.  Distribution of inflammatory cells in adventitia changed with advancing atherosclerosis of human coronary artery.

Authors:  Makoto Watanabe; Akiko Sangawa; Yoshifumi Sasaki; Maiko Yamashita; Michiko Tanaka-Shintani; Masayuki Shintaku; Yuichi Ishikawa
Journal:  J Atheroscler Thromb       Date:  2007-12-17       Impact factor: 4.928

8.  The antibody targeting the E314 peptide of human Kv1.3 pore region serves as a novel, potent and specific channel blocker.

Authors:  Xiao-Fang Yang; Yong Yang; Yi-Tian Lian; Zhao-Hui Wang; Xiao-Wei Li; Long-Xian Cheng; Jin-Ping Liu; Yan-Fu Wang; Xiang Gao; Yu-Hua Liao; Min Wang; Qiu-Tang Zeng; Kun Liu
Journal:  PLoS One       Date:  2012-04-27       Impact factor: 3.240

9.  Specific antibodies to the external vestibule of voltage-gated potassium channels block current.

Authors:  B Y Zhou; W Ma; X Y Huang
Journal:  J Gen Physiol       Date:  1998-04       Impact factor: 4.086

10.  Reduced expression of ATP-binding cassette transporter G1 increases cholesterol accumulation in macrophages of patients with type 2 diabetes mellitus.

Authors:  Jeremy P Mauldin; Melissa H Nagelin; Allison J Wojcik; Suseela Srinivasan; Marcus D Skaflen; Carlos R Ayers; Coleen A McNamara; Catherine C Hedrick
Journal:  Circulation       Date:  2008-05-19       Impact factor: 29.690

View more
  7 in total

Review 1.  Discovery of KV 1.3 ion channel inhibitors: Medicinal chemistry approaches and challenges.

Authors:  Špela Gubič; Louise A Hendrickx; Žan Toplak; Maša Sterle; Steve Peigneur; Tihomir Tomašič; Luis A Pardo; Jan Tytgat; Anamarija Zega; Lucija P Mašič
Journal:  Med Res Rev       Date:  2021-05-01       Impact factor: 12.944

Review 2.  Mechanisms of foam cell formation in atherosclerosis.

Authors:  Dimitry A Chistiakov; Alexandra A Melnichenko; Veronika A Myasoedova; Andrey V Grechko; Alexander N Orekhov
Journal:  J Mol Med (Berl)       Date:  2017-08-07       Impact factor: 4.599

3.  Voltage Gated Potassium Channel Kv1.3 Is Upregulated on Activated Astrocytes in Experimental Autoimmune Encephalomyelitis.

Authors:  Iva Bozic; Katarina Tesovic; Danijela Laketa; Marija Adzic; Marija Jakovljevic; Ivana Bjelobaba; Danijela Savic; Nadezda Nedeljkovic; Sanja Pekovic; Irena Lavrnja
Journal:  Neurochem Res       Date:  2018-03-24       Impact factor: 3.996

Review 4.  Critical regulation of atherosclerosis by the KCa3.1 channel and the retargeting of this therapeutic target in in-stent neoatherosclerosis.

Authors:  Yan-Rong Zhu; Xiao-Xin Jiang; Dai-Min Zhang
Journal:  J Mol Med (Berl)       Date:  2019-06-28       Impact factor: 4.599

5.  Selective Kv1.3 channel blocker as therapeutic for obesity and insulin resistance.

Authors:  Sanjeev Kumar Upadhyay; Kristin L Eckel-Mahan; M Reza Mirbolooki; Indra Tjong; Stephen M Griffey; Galina Schmunk; Amanda Koehne; Briac Halbout; Shawn Iadonato; Brian Pedersen; Emiliana Borrelli; Ping H Wang; Jogeshwar Mukherjee; Paolo Sassone-Corsi; K George Chandy
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-31       Impact factor: 11.205

6.  Kv1.5 channel mediates monosodium urate-induced activation of NLRP3 inflammasome in macrophages and arrhythmogenic effects of urate on cardiomyocytes.

Authors:  Peili Li; Yasutaka Kurata; Fikri Taufiq; Masanari Kuwabara; Haruaki Ninomiya; Katsumi Higaki; Motokazu Tsuneto; Yasuaki Shirayoshi; Miguel A Lanaspa; Ichiro Hisatome
Journal:  Mol Biol Rep       Date:  2022-04-04       Impact factor: 2.742

Review 7.  Macrophage-mediated cholesterol handling in atherosclerosis.

Authors:  Dimitry A Chistiakov; Yuri V Bobryshev; Alexander N Orekhov
Journal:  J Cell Mol Med       Date:  2015-10-23       Impact factor: 5.310

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.